<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01108458</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-18227</org_study_id>
    <secondary_id>SU-03082010-5163</secondary_id>
    <secondary_id>PANC0010</secondary_id>
    <nct_id>NCT01108458</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma</brief_title>
  <official_title>A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>George Albert Fisher</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2 study combining pertuzumab with erlotinib for patients with gemcitabine refractory
      pancreatic adenocarcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single-institution, single-arm phase 2 study investigating pertuzumab and erlotinib as a
      palliative regimen in the treatment of locally-advanced or metastatic pancreatic
      adenocarcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Extreme toxicity of Pertuzumab and Erlotinib combination
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate by RECIST Criteria</measure>
    <time_frame>CT imaging every 9 weeks while on protocol</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>9 weeks</time_frame>
    <description>Disease status evaluated by computed tomography (CT) scan and progression-free survival assessed per RECIST criteria.
Tumor response was assessed by the IRF according to RECIST v1.1. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (&lt;) 10 millimeters (mm). PR was defined as greater than or equal to (≥) 30 percent (%) decrease in sum of longest diameter (LD) of target lesions in reference to Baseline sum LD. Response was to be confirmed ≥4 weeks after the initial assessment of CR or PR. The percentage of participants with a confirmed objective response of CR or PR was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>3 weeks</time_frame>
    <description>Quality of life as assessed by EORTC QLQ-C30 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No. of Events of Drug-related Toxicity</measure>
    <time_frame>3 weeks</time_frame>
    <description>Number of incidences of serious and non-serious drug-related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With 50% Decrease in Tumor Marker</measure>
    <time_frame>3 weeks</time_frame>
    <description>Change in tumor marker CA19-9, assessed as a 50% decrease from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Pertuzumab plus Erlotinib Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pertuzumab 840 mg intravenous (IV) single loading dose followed by 420 mg IV every 3 weeks
Erlotinib hydrochloride 150 mg/day by mouth</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>iv, 840 mg, 420 mg</description>
    <arm_group_label>Pertuzumab plus Erlotinib Hydrochloride</arm_group_label>
    <other_name>2C4</other_name>
    <other_name>Omnitarg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>PO, 150 mg</description>
    <arm_group_label>Pertuzumab plus Erlotinib Hydrochloride</arm_group_label>
    <other_name>Erlotinib hydrochloride</other_name>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        3.1 Inclusion Criteria

        3.1.1 Histologically-confirmed pancreatic adenocarcinoma

        3.1.2 One or more locally-advanced or metastatic lesions measurable in at least one
        dimension by modified RECIST criteria (v1.1)^13 within 4 weeks prior to entry of study

        3.1.3 Prior therapy (1 or more):

        3.1.3.1 Disease progression following therapy with gemcitabine

        3.1.3.2 Intolerance to gemcitabine

        3.1.3.3 Disease recurrence within 12 months following adjuvant gemcitabine

        3.1.4 Age &gt;= 18

        3.1.5 ECOG performance status 0-2

        3.1.6 Laboratory values &lt;= 2 weeks prior to enrollment:

          -  Absolute neutrophil count (ANC) &gt;= 1.5 x 10^9/L (&gt;= 1500/mm^3)

          -  Platelets (Plt) &gt;= 100,000/mm^3

          -  Hemoglobin (Hgb) &gt;= 9 g/dL

          -  Serum creatinine &lt;= 1.5 x ULN

          -  Serum bilirubin &lt;= 1.5 x ULN (&lt;= 3.0 x ULN if liver metastases present)

          -  Aspartate aminotransferase (AST/SGOT), alanine aminotransferase (ALT/SGPT) &lt;= 3.0 x
             ULN. (&lt;= 5.0 x ULN if liver metastases present). ERCP or percutaneous stenting may be
             used to normalize the liver function tests

        3.1.7 Echocardiogram or MUGA scan demonstrating LVEF &gt;= 50% within 4 weeks of trial entry

        3.1.8 Ability to understand and the willingness to sign a written informed consent
        document.

        Exclusion Criteria:

        3.2 Disease-Specific Exclusion Criteria

        3.2.1 Prior therapy with EGFR-targeted agents

        3.2.2 If history of other primary cancer, subject will be eligible only if she or he has:

          -  Curatively resected non-melanomatous skin cancer

          -  Curatively treated cervical carcinoma in situ

          -  Other primary solid tumor curatively treated with no known active disease present and
             no treatment administered for the last 3 years

        3.3 General Medical Exclusion Criteria

        3.3.1 Subjects known to have chronic or active hepatitis B or C infection with impaired
        hepatic function (ineligible if AST and ALT &gt; 3.0 x ULN).

        3.3.2 History of any medical or psychiatric condition or laboratory abnormality that in the
        opinion of the investigator may increase the risks associated with study participation or
        study drug administration or may interfere with the conduct of the study or interpretation
        of study results

        3.3.3 Male subject who is not willing to use adequate contraception upon enrollment into
        this study and for 6 months following the last dose of study agents

        3.3.4 Female subject (of childbearing potential, post-menopausal for less than 6 months,
        not surgically sterilized, or not abstinent) who is not willing to use an oral, patch or
        implanted contraceptive, double-barrier birth control, or an IUD during the course of the
        study and for 6 months following the last dose of second-line treatment

        3.3.5 Female subject who is breast-feeding or who has positive serum pregnancy test 72
        hours prior to enrollment

        3.3.6 Any of the following concurrent severe and/or uncontrolled medical conditions within
        24 weeks of enrollment which could compromise participation in the study:

          -  Unstable angina pectoris

          -  Symptomatic congestive heart failure

          -  Myocardial infarction &lt;= 6 months prior to registration and/or randomization

          -  Serious uncontrolled cardiac arrhythmia

          -  Uncontrolled diabetes

          -  Active or uncontrolled infection

          -  Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung

          -  Chronic renal disease

        3.3.7 Patients unwilling to or unable to comply with the protocol

        3.3.8 Current, recent (within 4 weeks of the first infusion of this study), or planned
        participation in an experimental drug study other than a Genentech/Roche sponsored cancer
        study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Albert Fisher M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2010</study_first_submitted>
  <study_first_submitted_qc>April 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2010</study_first_posted>
  <results_first_submitted>January 12, 2017</results_first_submitted>
  <results_first_submitted_qc>January 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 3, 2017</results_first_posted>
  <last_update_submitted>January 12, 2017</last_update_submitted>
  <last_update_submitted_qc>January 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>George Albert Fisher</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pertuzumab Plus Erlotinib Hydrochloride</title>
          <description>Pertuzumab 840 mg intravenous (IV) single loading dose followed by 420 mg IV every 3 weeks
Erlotinib hydrochloride 150 mg/day by mouth
Pertuzumab: iv, 840 mg, 420 mg
Erlotinib: PO, 150 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pertuzumab Plus Erlotinib Hydrochloride</title>
          <description>Pertuzumab 840 mg intravenous (IV) single loading dose followed by 420 mg IV every 3 weeks
Erlotinib hydrochloride 150 mg/day by mouth
Pertuzumab: iv, 840 mg, 420 mg
Erlotinib: PO, 150 mg</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate by RECIST Criteria</title>
        <time_frame>CT imaging every 9 weeks while on protocol</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pertuzumab Plus Erlotinib Hydrochloride</title>
            <description>Pertuzumab 840 mg intravenous (IV) single loading dose followed by 420 mg IV every 3 weeks
Erlotinib hydrochloride 150 mg/day by mouth
Pertuzumab: iv, 840 mg, 420 mg
Erlotinib: PO, 150 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate by RECIST Criteria</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Disease status evaluated by computed tomography (CT) scan and progression-free survival assessed per RECIST criteria.
Tumor response was assessed by the IRF according to RECIST v1.1. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (&lt;) 10 millimeters (mm). PR was defined as greater than or equal to (≥) 30 percent (%) decrease in sum of longest diameter (LD) of target lesions in reference to Baseline sum LD. Response was to be confirmed ≥4 weeks after the initial assessment of CR or PR. The percentage of participants with a confirmed objective response of CR or PR was reported.</description>
        <time_frame>9 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pertuzumab Plus Erlotinib Hydrochloride</title>
            <description>Pertuzumab 840 mg intravenous (IV) single loading dose followed by 420 mg IV every 3 weeks
Erlotinib hydrochloride 150 mg/day by mouth
Pertuzumab: iv, 840 mg, 420 mg
Erlotinib: PO, 150 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Disease status evaluated by computed tomography (CT) scan and progression-free survival assessed per RECIST criteria.
Tumor response was assessed by the IRF according to RECIST v1.1. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (&lt;) 10 millimeters (mm). PR was defined as greater than or equal to (≥) 30 percent (%) decrease in sum of longest diameter (LD) of target lesions in reference to Baseline sum LD. Response was to be confirmed ≥4 weeks after the initial assessment of CR or PR. The percentage of participants with a confirmed objective response of CR or PR was reported.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pertuzumab Plus Erlotinib Hydrochloride</title>
            <description>Pertuzumab 840 mg intravenous (IV) single loading dose followed by 420 mg IV every 3 weeks
Erlotinib hydrochloride 150 mg/day by mouth
Pertuzumab: iv, 840 mg, 420 mg
Erlotinib: PO, 150 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (QoL)</title>
        <description>Quality of life as assessed by EORTC QLQ-C30 questionnaire</description>
        <time_frame>3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pertuzumab Plus Erlotinib Hydrochloride</title>
            <description>Pertuzumab 840 mg intravenous (IV) single loading dose followed by 420 mg IV every 3 weeks
Erlotinib hydrochloride 150 mg/day by mouth
Pertuzumab: iv, 840 mg, 420 mg
Erlotinib: PO, 150 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life (QoL)</title>
          <description>Quality of life as assessed by EORTC QLQ-C30 questionnaire</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>No. of Events of Drug-related Toxicity</title>
        <description>Number of incidences of serious and non-serious drug-related adverse events</description>
        <time_frame>3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pertuzumab Plus Erlotinib Hydrochloride</title>
            <description>Pertuzumab 840 mg intravenous (IV) single loading dose followed by 420 mg IV every 3 weeks
Erlotinib hydrochloride 150 mg/day by mouth
Pertuzumab: iv, 840 mg, 420 mg
Erlotinib: PO, 150 mg</description>
          </group>
        </group_list>
        <measure>
          <title>No. of Events of Drug-related Toxicity</title>
          <description>Number of incidences of serious and non-serious drug-related adverse events</description>
          <units>Drug-related adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With 50% Decrease in Tumor Marker</title>
        <description>Change in tumor marker CA19-9, assessed as a 50% decrease from baseline</description>
        <time_frame>3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pertuzumab Plus Erlotinib Hydrochloride</title>
            <description>Pertuzumab 840 mg intravenous (IV) single loading dose followed by 420 mg IV every 3 weeks
Erlotinib hydrochloride 150 mg/day by mouth
Pertuzumab: iv, 840 mg, 420 mg
Erlotinib: PO, 150 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With 50% Decrease in Tumor Marker</title>
          <description>Change in tumor marker CA19-9, assessed as a 50% decrease from baseline</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pertuzumab Plus Erlotinib Hydrochloride</title>
          <description>Pertuzumab 840 mg intravenous (IV) single loading dose followed by 420 mg IV every 3 weeks
Erlotinib hydrochloride 150 mg/day by mouth
Pertuzumab: iv, 840 mg, 420 mg
Erlotinib: PO, 150 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE 3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE v3">Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>George Albert Fisher, MD</name_or_title>
      <organization>Stanford University Medical Center</organization>
      <phone>650-725-9057</phone>
      <email>georgeaf@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

